Notably, the combined application of shikonin and PD-1 treatment substantially enhanced the recruitment and infiltration of CD8+ T cells into the tumor microenvironment, thereby altering the immune conditions within the tumor (Chen et al., 2024). This evidence concerns the gene CD8A and neoplasm.